ImmunityBio, Inc. Profile Avatar - Palmy Investing

ImmunityBio, Inc.

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulato…

Biotechnology
US, San Diego [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

ImmunityBio, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of IBRX's Analysis
CIK: 1326110 CUSIP: 45256X103 ISIN: US45256X1037 LEI: - UEI: -
Secondary Listings
IBRX has no secondary listings inside our databases.